DT Midstream
reached final investment decision on system phase expansion expanding leap from to | DT Midstream
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
10 of 26
Related slides by other companies
AstraZeneca
Investor Day
September 2022
supports further indication expansion | AstraZeneca
Alkermes
Results
June 2021
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
Alkermes
Investor Day
March 2021
artistry determined selected as recommended phase dose for artistry efficacy expansion stage selection of based on totality of data including safety and efficacy during dose phase acceptable safety and tolerability profile consistent with the anticipated pharmacological effect and that observed with intravenous dose dependent increases in cell and cell activation and minimal increase in clinical benefit stable disease observed additional artistry data to be presented at future medical meeting phase efficacy expansion initiated based on totality of dose data regulatory cell natural killer pharmacodynamic | Alkermes
Kymera
Investor Presentation
December 2023
| Kymera
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights